Basic Information
RNALocate ID: | RLID:01001763 |
RNA Symbol: | hsa-miR-130a-3p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-130a |
RNA ID: | miRBase:MIMAT0000425 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21363885 |
Tissue/Cell Line: | Neural progenitor cells |
Method: | Microarray|qRT-PCR |
Description: | The miRNAs with nuclear or cytoplasmic dominance are shown in Table 1 (complete data in Supplement 4). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001764 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001765 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001766 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001767 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001768 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001769 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11001726 | Exosome | Serum | 29143228 |
RLID:11001727 | Exosome | Primary dendritic cells | 21505438 |
RLID:11001728 | Exosome | Breast milk | 22211110 |
RLID:11001729 | Exosome | Brain tissue | 23382797 |
RLID:11001730 | Exosome | Plasma | 23663360 |
RLID:11001731 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11001732 | Microvesicle | Plasma | 23077538 |
RLID:11001733 | Microvesicle | Seminal plasma | 23539611 |
RLID:11001734 | Microvesicle | Follicular fluid | 23666971 |
RLID:11001735 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000078 | Exosome | Blood|Endothelial cells | |
RLID-D:11000353 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-130a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-10672 |
MNDR | hsa-miR-130a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-10673 |
MNDR | hsa-miR-130a-3p | Peripheral artery disease | MNDR-E-MI-10674 |
MNDR | hsa-miR-130a-3p | Oral squamous cell carcinoma | MNDR-E-MI-10675 |
MNDR | hsa-miR-130a-3p | Medulloblastoma | MNDR-E-MI-10676 |
MNDR | hsa-miR-130a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-10677 |
MNDR | hsa-miR-130a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-10678 |
MNDR | hsa-miR-130a-3p | Spinocerebellar ataxia type 1 | MNDR-E-MI-10679 |
MNDR | hsa-miR-130a-3p | Lymphoma | MNDR-E-MI-10680 |
MNDR | hsa-miR-130a-3p | Lymphoma non-hodgkin | MNDR-E-MI-10681 |
MNDR | hsa-miR-130a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-10682 |
MNDR | hsa-miR-130a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-10683 |
MNDR | hsa-miR-130a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-10684 |
MNDR | hsa-miR-130a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-10685 |
MNDR | hsa-miR-130a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-10686 |
MNDR | hsa-miR-130a-3p | Breast cancer luminal | MNDR-E-MI-10687 |
MNDR | hsa-miR-130a-3p | Myeloid neoplasm | MNDR-E-MI-10688 |
MNDR | hsa-miR-130a-3p | Niemann-pick disease type c | MNDR-E-MI-10689 |
MNDR | hsa-miR-130a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-10690 |
MNDR | hsa-miR-130a-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-10691 |
MNDR | hsa-miR-130a-3p | Autosomal recessive limb-girdle muscular dystrophy type 2a | MNDR-E-MI-10692 |
MNDR | hsa-miR-130a-3p | Dermatomyositis | MNDR-E-MI-10693 |
MNDR | hsa-miR-130a-3p | Prostate cancer | MNDR-E-MI-10694 |
MNDR | hsa-miR-130a-3p | Prostate carcinoma | MNDR-E-MI-10695 |
MNDR | hsa-miR-130a-3p | Chronic lymphocytic leukemia | MNDR-E-MI-10696 |
MNDR | hsa-miR-130a-3p | Gastric cancer | MNDR-E-MI-10697 |
MNDR | hsa-miR-130a-3p | Gastric lymphoma | MNDR-E-MI-10698 |
MNDR | hsa-miR-130a-3p | Alzheimer disease | MNDR-E-MI-10699 |
MNDR | hsa-miR-130a-3p | Attention deficit hyperactivity disorder | MNDR-E-MI-10700 |
MNDR | hsa-miR-130a-3p | Intracranial aneurysm | MNDR-E-MI-10701 |
MNDR | hsa-miR-130a-3p | Bladder cancer | MNDR-E-MI-10702 |
MNDR | hsa-miR-130a-3p | Dysautonomia familial | MNDR-E-MI-10703 |
MNDR | hsa-miR-130a-3p | Muscular dystrophy duchenne | MNDR-E-MI-10704 |
MNDR | hsa-miR-130a-3p | Seizures | MNDR-E-MI-10705 |
MNDR | hsa-miR-130a-3p | Head and neck cancer | MNDR-E-MI-10706 |
MNDR | hsa-miR-130a-3p | Leukemia | MNDR-E-MI-10707 |
MNDR | hsa-miR-130a-3p | Friedreich ataxia | MNDR-E-MI-10708 |
MNDR | hsa-miR-130a-3p | Huntington disease | MNDR-E-MI-10709 |
MNDR | hsa-miR-130a-3p | Cardiovascular disease | MNDR-E-MI-10710 |
MNDR | hsa-miR-130a-3p | Carotid stenosis | MNDR-E-MI-10711 |
MNDR | hsa-miR-130a-3p | Moyamoya disease | MNDR-E-MI-10712 |
MNDR | hsa-miR-130a-3p | Lung cancer | MNDR-E-MI-10713 |
MNDR | hsa-miR-130a-3p | Parkinson disease | MNDR-E-MI-10714 |
MNDR | hsa-miR-130a-3p | Niemann-pick disease | MNDR-E-MI-10715 |
MNDR | hsa-miR-130a-3p | Basal-like breast cancer | MNDR-E-MI-10716 |
MNDR | hsa-miR-130a-3p | Neuroendocrine neoplasia | MNDR-E-MI-10717 |
MNDR | hsa-miR-130a-3p | Thyroid cancer | MNDR-E-MI-10718 |
MNDR | hsa-miR-130a-3p | Pancreatic cancer | MNDR-E-MI-10719 |
MNDR | hsa-miR-130a-3p | Rectum adenocarcinoma | MNDR-E-MI-10720 |
MNDR | hsa-miR-130a-3p | Nephroblastoma | MNDR-E-MI-10721 |
MNDR | hsa-miR-130a-3p | Colon cancer | MNDR-E-MI-10722 |
MNDR | hsa-miR-130a-3p | Ischemic attack transient | MNDR-E-MI-10723 |
MNDR | hsa-miR-130a-3p | Colon adenocarcinoma | MNDR-E-MI-10724 |
MNDR | hsa-miR-130a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-10725 |
MNDR | hsa-miR-130a-3p | Ovarian cancer | MNDR-E-MI-10726 |
MNDR | hsa-miR-130a-3p | Prostate adenocarcinoma | MNDR-E-MI-10727 |
MNDR | hsa-miR-130a-3p | Infantile hemangioma | MNDR-E-MI-10728 |
MNDR | hsa-miR-130a-3p | Carcinoma ductal breast | MNDR-E-MI-10729 |
MNDR | hsa-miR-130a-3p | Invasive ductal carcinoma | MNDR-E-MI-10730 |
MNDR | hsa-miR-130a-3p | Glioblastoma | MNDR-E-MI-10731 |
MNDR | hsa-miR-130a-3p | Astrocytoma | MNDR-E-MI-10732 |
MNDR | hsa-miR-130a-3p | Glioma | MNDR-E-MI-10733 |
MNDR | hsa-miR-130a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-10734 |
MNDR | hsa-miR-130a-3p | Nemaline myopathy | MNDR-E-MI-10735 |
MNDR | hsa-miR-130a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-10736 |
MNDR | hsa-miR-130a-3p | Temporal lobe epilepsy | MNDR-E-MI-10737 |
MNDR | hsa-miR-130a-3p | Osteosarcoma | MNDR-E-MI-10738 |
MNDR | hsa-miR-130a-3p | Coronary artery disease | MNDR-E-MI-10739 |
MNDR | hsa-miR-130a-3p | Meningioma | MNDR-E-MI-10740 |
MNDR | hsa-miR-130a-3p | Liver cancer | MNDR-E-MI-10741 |
MNDR | hsa-miR-130a-3p | Uterine cancer | MNDR-E-MI-10742 |
MNDR | hsa-miR-130a-3p | Gastric adenocarcinoma | MNDR-E-MI-10743 |
MNDR | hsa-miR-130a-3p | Lung squamous cell carcinoma | MNDR-E-MI-10744 |
MNDR | hsa-miR-130a-3p | Carcinoma lung non-small-cell | MNDR-E-MI-10745 |
MNDR | hsa-miR-130a-3p | Lung adenocarcinoma | MNDR-E-MI-10746 |
MNDR | hsa-miR-130a-3p | Thyroid carcinoma | MNDR-E-MI-10747 |
MNDR | hsa-miR-130a-3p | Bladder urothelial carcinoma | MNDR-E-MI-10748 |
MNDR | hsa-miR-130a-3p | Brain stem cancer | MNDR-E-MI-10749 |
MNDR | hsa-miR-130a-3p | Cervical cancer | MNDR-E-MI-10750 |
MNDR | hsa-miR-130a-3p | Carcinoma renal cell | MNDR-E-MI-10751 |
MNDR | hsa-miR-130a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-10752 |
MNDR | hsa-miR-130a-3p | Adenocarcinoma clear cell | MNDR-E-MI-10753 |
MNDR | hsa-miR-130a-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-10754 |
MNDR | hsa-miR-130a-3p | Brain edema | MNDR-E-MI-10755 |
MNDR | hsa-miR-130a-3p | Cholangiocarcinoma | MNDR-E-MI-10756 |
MNDR | hsa-miR-130a-3p | Esophageal cancer | MNDR-E-MI-10757 |
MNDR | hsa-miR-130a-3p | Lung small cell carcinoma | MNDR-E-MI-10758 |
MNDR | hsa-miR-130a-3p | Synovial sarcoma | MNDR-E-MI-10759 |
MNDR | hsa-miR-130a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-10760 |
MNDR | hsa-miR-130a-3p | T acute lymphoblastic leukemia | MNDR-E-MI-10761 |
MNDR | hsa-miR-130a-3p | Acute t cell leukemia | MNDR-E-MI-10762 |
MNDR | hsa-miR-130a-3p | Fibromyalgia | MNDR-E-MI-10763 |
MNDR | hsa-miR-130a-3p | Breast invasive carcinoma | MNDR-E-MI-10764 |
MNDR | hsa-miR-130a-3p | Hepatocellular carcinoma | MNDR-E-MI-10765 |
MNDR | hsa-miR-130a-3p | B-cell lymphoma | MNDR-E-MI-10766 |
MNDR | hsa-miR-130a-3p | Rheumatoid arthritis | MNDR-E-MI-10767 |
MNDR | hsa-miR-130a-3p | Hodgkin lymphoma | MNDR-E-MI-10768 |
MNDR | hsa-miR-130a-3p | Burkitt lymphoma | MNDR-E-MI-10769 |
MNDR | hsa-miR-130a-3p | Tonsil cancer | MNDR-E-MI-10770 |
MNDR | hsa-miR-130a-3p | Neuromyelitis optica | MNDR-E-MI-10771 |
MNDR | hsa-miR-130a-3p | Psoriasis | MNDR-E-MI-10772 |
MNDR | hsa-miR-130a-3p | Acute myelocytic leukemia | MNDR-E-MI-10773 |
MNDR | hsa-miR-130a-3p | Colorectal cancer | MNDR-E-MI-10774 |
MNDR | hsa-miR-130a-3p | Nasopharyngeal carcinoma | MNDR-E-MI-10775 |
MNDR | hsa-miR-130a-3p | Nasopharynx carcinoma | MNDR-E-MI-10776 |
MNDR | hsa-miR-130a-3p | Diabetes mellitus | MNDR-E-MI-10777 |
MNDR | hsa-miR-130a-3p | Type 2 diabetes mellitus | MNDR-E-MI-10778 |
MNDR | hsa-miR-130a-3p | Multiple myeloma | MNDR-E-MI-10779 |
MNDR | hsa-miR-130a-3p | Ovarian epithelial cancer | MNDR-E-MI-10780 |
MNDR | hsa-miR-130a-3p | Ependymoma | MNDR-E-MI-10781 |
MNDR | hsa-miR-130a-3p | Nasopharyngeal cancer | MNDR-E-MI-10782 |
MNDR | hsa-miR-130a-3p | Aids dementia complex | MNDR-E-MI-10783 |
MNDR | hsa-miR-130a-3p | Polymyositis | MNDR-E-MI-10784 |
MNDR | hsa-miR-130a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-10785 |
MNDR | hsa-miR-130a-3p | Gait ataxia | MNDR-E-MI-10786 |
MNDR | hsa-miR-130a-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-10787 |
MNDR | hsa-miR-130a-3p | Stroke lacunar | MNDR-E-MI-10788 |
MNDR | hsa-miR-130a-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-10789 |
MNDR | hsa-miR-130a-3p | Breast cancer her3+ negative | MNDR-E-MI-10790 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACVR1 | Homo sapiens | RR00038727 |
TOP